BioCentury
ARTICLE | Company News

Oxford BioMedica, sanofi-aventis deal

May 4, 2009 7:00 AM UTC

sanofi-aventis returned to Oxford BioMedica rights to TroVax following a review of the pharma's R&D portfolio. Oxford BioMedica will receive a $16.5 million payment, including a settlement of previou...